Navigation Links
Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results
Date:5/15/2009

,940 CASH FLOWS FROM INVESTING ACTIVITIES: Other receivables - related party -- 2,570,100 Purchase plant and equipment (9,679) (154,262) Proceeds from equipment disposal 5,125,750 35,266 Additions to construction in progress (4,810,511) (7,725,153) Acquisition of land use right (480,356) (324,031) Purchase of software program -- (5,426) Advances on plant and equipment purchase -- (9,876,385) Loan repayment from related party -- 678,200 Proceed from land use right disposal -- 30,826 Net cash used in investing activities (174,796) (14,770,865) CASH FLOWS FROM FINANCING ACTIVITIES: Decrease in restricted cash (2,201,573) 3,407,360 Borrowings on notes payable - banks 16,607,430 5,425,600 Payments on notes payable - banks (14,410,680) (10,579,920) Borrowings on short term loans 13,722,365 12,750,160 Payments on short term loans (13,766,300) (11,380,196) Borrowings on employee loans 392,147 1,412,554 Payments on employee loans (938,635) (459,082) Borrowings on employee loan - officer -- 45,187 Other receivables - shareholder (10,252) 1,273,495 Borrowings on third party loan 113,650 2,898,529 Payments on third party loan (563,715) (2,826,195) Payment on other payable - equipment purchase (1,033,127) (614,633) Cash pro
'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call
2. Shengtai Pharmaceutical Hosts Key Customers at Its Headquarters for Facility Tour and Technology Exchange Conference
3. Shengtai Pharmaceutical, Inc. Comments On Its Operations
4. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
5. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
6. Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference
7. Shengtai Pharmaceutical Expands International Sales Program
8. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
9. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
10. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
11. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Roche Diagnostics Opens State-of-the-Art Training Center in California 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4Organization Announces End Prostate Cancer Tour 49229 1Organization Announces End Prostate Cancer Tour 49229 2Organization Announces End Prostate Cancer Tour 49229 3Ruben Studdard American Idol Winner and R 26B Pop Star Spreads the Word about Sickle Cell Disease and the Dangers of Iron Overload 49226 1Ruben Studdard American Idol Winner and R 26B Pop Star Spreads the Word about Sickle Cell Disease and the Dangers of Iron Overload 49226 2Ruben Studdard American Idol Winner and R 26B Pop Star Spreads the Word about Sickle Cell Disease and the Dangers of Iron Overload 49226 3AARP Others Push for Health Parity for Puerto Rico 49223 1AARP Others Push for Health Parity for Puerto Rico 49223 2